A feasibility study: Improving management of comorbidity in patients with colorectal cancer

ABSTRACT: Interventions: This is a non-randomised sequential cohort study with a control phase followed by an intervention phase and finally a qualitative phase to fully assess study feasibility. Patient diagnosis date will determine whether they are invited to participate within the control or intervention phase of the study. All patients who consent will be screened for comorbidity by completing a health questionnaire (taking up to 30 minutes) and medical note review by a research nurse. The nurse will assess the patient’s eligibility to be referred to the intervention using defined decision-making criteria. Patients within the intervention arm who are identified as being eligible will be invited to attend a Comprehensive Medical Assessment (CMA) completed by a study specific Geriatrician within Older Persons’ Health outpatient clinics single session. Each CMA will take 30-60 minutes to complete. The CMA will be tailored to each patient, will cover a) assessment and management of comorbidity; b) assessment and management of polypharmacy; c) evaluation of mental health with a particular focus on depression; and d) review of functional and psychosocial issues, and will result in patient specific care plans. On-going geriatrician management will be determined on a case by case basis. Geriatrician clinical notes and letters will be reviewed to obtain study data pertaining to each patients specific care plan, and to assess intervention fidelity. Primary outcome(s): Whether the study forms, processes and procedures are acceptable and feasibile to enact. This will be assessed by tracking recruitment numbers overall, assessing the proportion of patients who fulfil eligiblity criteria to proceed to CMA and the proportion CMA eligibile intervention arm patients who consent to CMA, and through qualitative feedback from participants (including patients, research nurses and clinicians) . [1 year post enrollment in the study];Chemotherapy uptake rates. This will be assessed and collected by study-specific research coordinators on standardised proforma through manual review of patient’s medical notes.[1 year post enrollment in the study];Chemotherapy completion - as planned - rates. This will be assessed and collected by study-specific research coordinators on standardised proforma through manual review of patient’s medical notes.[1 year post enrollment in the study] Study Design: Purpose: Treatment; Allocation: Non-randomised trial; Masking: Open (masking not used);Assignment: Other

DISEASE(S): Comorbidity,Colorectal Cancer,Cancer-bowel-back Passage (rectum) Or Large Bowel (colon)

PROVIDER: 2469631 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR